| AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight (NCT07668401) | Novo Nordisk A/S | 2027-01-07 |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide (NCT07668414) | Novo Nordisk A/S | 2026-09-22 |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes (NCT07357740) | Novo Nordisk A/S | 2026-08-27 |
| Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance (NCT07769489) | Novo Nordisk A/S | 2026-08-17 |
| Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight (NCT07770841) | Novo Nordisk A/S | 2026-08-12 |
| A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity (NCT07767175) | Novo Nordisk A/S | 2026-08-12 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (NCT07282613) | Novo Nordisk A/S | 2026-08-04 |
| A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo (NCT07757087) | Novo Nordisk A/S | 2026-08-03 |
| A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant (NCT07710729) | Novo Nordisk A/S | 2026-07-17 |
| A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight (NCT07710768) | Novo Nordisk A/S | 2026-07-15 |
| Korean Real-world Study on MASLD/MASH Outcomes. (NCT07739901) | Novo Nordisk A/S | 2026-07-13 |
| Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany (NCT07653139) | Novo Nordisk A/S | 2026-07-10 |
| A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity (NCT07693868) | Novo Nordisk A/S | 2026-07-06 |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight (NCT07357766) | Novo Nordisk A/S | 2026-06-22 |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes (NCT07668388) | Novo Nordisk A/S | 2026-06-22 |
| A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants (NCT07656454) | Novo Nordisk A/S | 2026-06-17 |
| Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec (NCT07658417) | Novo Nordisk A/S | 2026-06-15 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity (NCT07639021) | Novo Nordisk A/S | 2026-06-09 |
| Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study (NCT07673822) | Novo Nordisk A/S | 2026-06-08 |
| A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec (NCT07632404) | Novo Nordisk A/S | 2026-06-05 |
| Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians (NCT07682363) | Novo Nordisk A/S | 2026-06-03 |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events (NCT07607587) | Novo Nordisk A/S | 2026-05-29 |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight (NCT07564414) | Novo Nordisk A/S | 2026-05-21 |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight (NCT07605052) | Novo Nordisk A/S | 2026-05-20 |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (NCT07400107) | Novo Nordisk A/S | 2026-05-20 |
| Weight Loss in Adults Using Semaglutide (Real-world Study) (NCT07627074) | Novo Nordisk A/S | 2026-05-12 |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity (NCT07567001) | Novo Nordisk A/S | 2026-05-11 |
| A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity (NCT07578584) | Novo Nordisk A/S | 2026-05-07 |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea (NCT07571005) | Novo Nordisk A/S | 2026-05-05 |
| A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM (NCT07570992) | Novo Nordisk A/S | 2026-05-04 |
| A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity (NCT07566390) | Novo Nordisk A/S | 2026-05-01 |
| A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity (NCT07557953) | Novo Nordisk A/S | 2026-04-30 |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss (NCT07503210) | Novo Nordisk A/S | 2026-04-21 |
| AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (NCT07509307) | Novo Nordisk A/S | 2026-04-20 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes (NCT07415954) | Novo Nordisk A/S | 2026-04-17 |
| A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (NCT07481630) | Novo Nordisk A/S | 2026-04-13 |
| AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (NCT07533175) | Novo Nordisk A/S | 2026-04-13 |
| Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes (NCT07535307) | Novo Nordisk A/S | 2026-04-10 |
| Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) (NCT07527195) | Novo Nordisk A/S | 2026-04-10 |
| A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight (NCT07525791) | Novo Nordisk A/S | 2026-04-07 |
| A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity (NCT07508020) | Novo Nordisk A/S | 2026-03-30 |
| A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants (NCT07532863) | Novo Nordisk A/S | 2026-03-13 |
| A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis. (NCT07448623) | Novo Nordisk A/S | 2026-03-02 |
| A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity (NCT07437079) | Novo Nordisk A/S | 2026-02-24 |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight (NCT07339423) | Novo Nordisk A/S | 2026-02-24 |
| A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China (NCT07456774) | Novo Nordisk A/S | 2026-02-13 |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (NCT07411560) | Novo Nordisk A/S | 2026-02-09 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (NCT05689372) | Novo Nordisk A/S | 2026-02-02 |
| A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity (NCT07395687) | Novo Nordisk A/S | 2026-02-02 |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (NCT07253285) | Novo Nordisk A/S | 2026-01-08 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (NCT05714683) | Novo Nordisk A/S | 2025-12-31 |
| Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma (NCT07713901) | Novo Nordisk A/S | 2025-12-31 |
| A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack (NCT07301034) | Novo Nordisk A/S | 2025-12-18 |
| A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes (NCT07305805) | Novo Nordisk A/S | 2025-12-16 |
| Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE） (NCT07358052) | Novo Nordisk A/S | 2025-12-08 |
| A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes (NCT07271251) | Novo Nordisk A/S | 2025-12-01 |
| A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes (NCT07270731) | Novo Nordisk A/S | 2025-11-25 |
| A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People (NCT07238816) | Novo Nordisk A/S | 2025-11-18 |
| WEgovy Real World Assessment of Weight Loss in Korea (NCT07280221) | Novo Nordisk A/S | 2025-11-10 |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) (NCT07225816) | Novo Nordisk A/S | 2025-11-07 |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (NCT07220759) | Novo Nordisk A/S | 2025-11-05 |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (NCT07220642) | Novo Nordisk A/S | 2025-11-05 |
| A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A (NCT07220564) | Novo Nordisk A/S | 2025-10-23 |
| A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure (NCT07218627) | Novo Nordisk A/S | 2025-10-23 |
| A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat (NCT07214870) | Novo Nordisk A/S | 2025-10-08 |
| CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (NCT07207811) | Novo Nordisk A/S | 2025-10-02 |
| A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population (NCT07201831) | Novo Nordisk A/S | 2025-10-02 |
| A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity (NCT07184632) | Novo Nordisk A/S | 2025-10-01 |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet (NCT07184086) | Novo Nordisk A/S | 2025-09-26 |
| Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study. (NCT07154238) | Novo Nordisk A/S | 2025-09-26 |
| Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management (NCT07160829) | Novo Nordisk A/S | 2025-09-18 |
| A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar (NCT07160816) | Novo Nordisk A/S | 2025-08-28 |
| A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India (NCT07157423) | Novo Nordisk A/S | 2025-08-26 |
| A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes (NCT07112339) | Novo Nordisk A/S | 2025-08-15 |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin. (NCT07121153) | Novo Nordisk A/S | 2025-08-11 |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (NCT07076199) | Novo Nordisk A/S | 2025-08-11 |
| A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany). (NCT07081178) | Novo Nordisk A/S | 2025-08-08 |
| Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 (NCT07153172) | Novo Nordisk A/S | 2025-08-06 |
| A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity (NCT07101783) | Novo Nordisk A/S | 2025-08-01 |
| User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes (NCT07052292) | Novo Nordisk A/S | 2025-07-01 |
| A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes (NCT07087795) | Novo Nordisk A/S | 2025-07-01 |
| A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy (NCT06979375) | Novo Nordisk A/S | 2025-06-30 |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy (NCT06979362) | Novo Nordisk A/S | 2025-06-27 |
| A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People (NCT07029568) | Novo Nordisk A/S | 2025-06-13 |
| The Role of the Amylin Analogue Cagrilintide in Bone Metabolism (NCT07010432) | Novo Nordisk A/S | 2025-06-12 |
| A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants (NCT07023029) | Novo Nordisk A/S | 2025-06-09 |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term (NCT07011667) | Novo Nordisk A/S | 2025-06-03 |
| A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (NCT07004322) | Novo Nordisk A/S | 2025-05-26 |
| Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo (NCT06831734) | Novo Nordisk A/S | 2025-05-02 |
| A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice (NCT07055607) | Novo Nordisk A/S | 2025-05-01 |
| Cities for Better Health Childhood Obesity Prevention Initiative (NCT06855563) | Novo Nordisk A/S | 2025-04-30 |
| General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus (NCT06807190) | Novo Nordisk A/S | 2025-04-15 |
| A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program (NCT06805539) | Novo Nordisk A/S | 2025-04-14 |
| CAPTIVATE India - A Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals With Type 2 Diabetes Mellitus (T2DM) in India (NCT07121114) | Novo Nordisk A/S | 2025-04-09 |
| Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam (NCT06843473) | Novo Nordisk A/S | 2025-03-18 |
| Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases (NCT06891365) | Novo Nordisk A/S | 2025-03-12 |
| A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease (NCT06612268) | Novo Nordisk A/S | 2025-02-17 |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity (NCT06780449) | Novo Nordisk A/S | 2025-02-10 |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (NCT06820476) | Novo Nordisk A/S | 2025-02-09 |
| A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants (NCT06813924) | Novo Nordisk A/S | 2025-02-06 |